ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic drugs"

  • Abstract Number: 1531 • 2015 ACR/ARHP Annual Meeting

    The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years

    Jean-Jacques Dubost1, Bruno Pereira2, Anne Tournadre3, Zuzana Tatar1, Marion Couderc1 and Martin Soubrier1, 1Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, 3Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France

    Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study…
  • Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting

    Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting

    Matthew Wong-Pack1, Rod Rodjanapiches1, Arthur Lau1,2,3, George Ioannidis1,3, Sally Wade4, Leslie Spangler4, Celia JF Lin4, Patrick Roy-Gayos1, William G Bensen1,3, Robert Bensen3 and Jonathan D Adachi1,3, 1McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 4Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
  • Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting

    Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA

    Peter C. Taylor1, Juan J Gomez-Reino2, Rieke Alten3, Philippe Bertin4, Roberto Caporali5, Emma Sullivan6, Robert Wood7, James Piercy7, Radu Vasilescu8, Dean Spurden9 and Jose Alvir10, 1Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, 2Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, 3Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4Rheumatology, CHU Dupuytren, Limoges, France, 5University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 6Adelphi Real World, Manchester, United Kingdom, 7Adelphi Real World, Macclesfield, United Kingdom, 8Medical Affairs, Pfizer Inc, Brussels, Belgium, 9Pfizer Inc, Tadworth, United Kingdom, 10Global Health and Value, Pfizer Inc, New York, NY

    Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…
  • Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting

    Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France

    Alexis Regent1, Serge Redeker2, Alban Deroux3, Pierre Kieffer4, Kim Heang Ly5, Maxime Dougados6, Claire Larroche7, Loïc Guillevin1, Laurence Bouillet8, Olivier Espitia9, Nathalie Costedoat-Chalumeau10, Martin Soubrier11, Benoit Brihaye12, François Lifermann13, Guillaume Lefèvre14, Xavier Puéchal1, Luc Mouthon1, Eric Toussirot15 and GFEV and CRI, 1Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 243 rue de l'isle, Ch Abbeville, Abbeville, France, 3Internal Medicine, CHU Grenoble, Grenoble, France, 4Hopital Emile Muller, Mulhouse Cedex 1, France, 5CHU de Limoges, Service de médecine interne, Limoges, France, 6Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, 7Internal Medicine, Paris, France, 8CHU, Grenoble, France, 9Internal Medicine, Nantes University Hospital, Nantes, France, 10Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 11Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 12Service de médecine interne et médecine polyvalente, Saint Quentin, France, 13CH Dax, Dax, France, 14Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, 15Service de Rhumatologie, CHU J Minjoz, Besancon, France

    Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…
  • Abstract Number: 432 • 2015 ACR/ARHP Annual Meeting

    Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-

    Tadashi Okano1, Kentaro Inui2, Masahiro Tada3, Yuko Sugioka4, Kenji Mamoto1, Tatsuya Koike4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Orthopedic surgery, Osaka City General Hospital, Osaka, Japan, 4Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: The latest recommendations for the treatment of rheumatoid arthritis (RA) focus on the achievement of clinical remission. However, joints with subclinical positive power Doppler…
  • Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition

    Alfons A. den Broeder1, Chantal A.M. Bouman1, Aatke van der Maas2, Frank H.J. van den Hoogen1, Noortje van Herwaarden1 and R. Landewe3, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, 3Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands

    Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
  • Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting

    Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate

    Clifton O. Bingham III1, Michael Weinblatt2, Rene Westhovens3, Lilianne Kim4, Chenglong Han5, Stephen Xu4, Kim Hung Lo4, Kezhen L. Tang4, Elizabeth C. Hsia4,6, Dennis Parenti7 and Shelly Kafka7, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Brigham and Women's Hospital, Boston, MA, 3UZ Gasthuisberg, Leuven, Belgium, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Global Services, LLC, Malvern, PA, 6University of Pennsylvania, Philadelphia, PA, 7Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…
  • Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting

    Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

    Alice B. Gottlieb1, Philip J. Mease2, Raquel S. Cuchacovich3,4, Catherine L. Shuler5, Chen-Yen Lin5, Russel T. Burge5, Suvajit Samanta5, Chin H. Lee5 and Dafna D. Gladman6, 1Dermatology, Tufts Medical Center, Boston, MA, 2Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, 3School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, 4Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Indianapolis, IN, 6Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
  • Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting

    Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis

    Cheryl Barnabe1, Yufei Zheng2, Arto Ohinmaa2, Brenda Hemmelgarn3, Gilaad Kaplan4, Liam Martin5 and Walter Maksymowych6, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada, 3Division of Nephrology, University of Calgary, Calgary, AB, Canada, 4Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, 5Medicine, University of Calgary, Calgary, AB, Canada, 6Medicine, Medicine, University of Alberta, Edmonton, AB, Canada

    Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
  • Abstract Number: 2336 • 2015 ACR/ARHP Annual Meeting

    Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis

    Steffen Jugl1, Sultana Syeda2 and Gunda Praveen2, 1BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland, 2Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India

    Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic progressive conditions with substantial humanistic burden on patients and care givers. A variety of instruments,…
  • Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting

    Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis

    Vidhu Anand1, Sachit Anand2, Sushil Garg3, Maria A. Lopez-Olivo4 and Jasvinder A. Singh5, 1University of Minnesota, Minneapolis, MN, 2All India Institute of Medical Sciences, New Delhi, India, 3The University of Minnesota, Minneapolis, MN, 4General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
  • Abstract Number: 2522 • 2015 ACR/ARHP Annual Meeting

    High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception

    Rebecca Fischer-Betz1, Oliver Sander1, Christof Specker2, Ralph Brinks3 and Matthias Schneider1, 1Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, 2Rheumatology and clinical immunology, Kliniken Essen Sued, Essen, Germany, 3Hiller Center for Research in Rheumatology, Duesseldorf, Germany

    Background/Purpose: Optimal treatment of women with Rheumatoid Arthritis (RA) during pregnancy remains a challenge, mainly due to safety concerns. TNF inhibitors (TNFi) are now routinely…
  • Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting

    Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes

    Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom

    Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
  • Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting

    Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)

    Polina Putrik1, Sofia Ramiro2, Elisabeth Lie3, Andras Keszei4, Desirée van der Heijde5, Robert Landewé6, Tore K. Kvien7, Till Uhlig7 and Annelies Boonen8, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, 5Leiden University Medical Center, Leiden, Netherlands, 6Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 7Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands

    Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…
  • Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting

    Durability of First Biologic Is Not Influenced By Initial/Early DAS28

    Gina Rohekar1, Binu Jacob2, Janet E. Pope3 and Claire Bombardier4, 1Rheumatology, St. Joseph's Hospital, London, ON, Canada, 2University Health Network, Toronto General Research Institute, Toronto, ON, Canada, 3Medicine, Western University, London, ON, Canada, 4Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose:   The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting.  Patients are enrolled and prospectively followed to…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology